Quintiles and Biogen Idec announce comprehensive clinical development partnership
24 April 2014 | By Biogen Idec
Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement...
List view / Grid view
News
AbbVie to present data on investigational compounds at the 2014 American Society of Clinical Oncology Annual Meeting
23 April 2014 | By AbbVie
AbbVie announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50th Annual Meeting of the American Society of Clinical Oncology...
Bristol-Myers Squibb and Samsung BioLogics expand manufacturing agreement
23 April 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site...
Pfizer announces positive top-line results from two Phase 3 trials of Tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
23 April 2014 | By Pfizer
Pfizer Inc. announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079)...
Biogen Idec first quarter 2014 revenues reach $2.1 billion driven by continued strength of MS franchise
23 April 2014 | By Biogen Idec
Biogen Idec Inc. reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013...
Enterome appoints Prof. Alessandra Cervino as Head of Discovery
22 April 2014 | By Enterome
ENTEROME bioscience SA is pleased to announce that Prof. Alessandra Cervino has joined the Company as Head of Discovery...
Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics
22 April 2014 | By Novartis
Novartis announced that it has reached a definitive agreement with GlaxoSmithKline plc to exchange certain assets, building global leadership in key segments and focusing the company's portfolio...
GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders
22 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses...
European Medicines Agency alerts EU healthcare professionals after vials of falsified Herceptin identified
17 April 2014 | By The European Medicines Agency
The European Medicines Agency has been informed that vials of the cancer medicine Herceptin (trastuzumab), thought to have been stolen in Italy, including from hospitals, have been tampered with and re-introduced under false credentials into the supply chain in some countries...
Volasertib, Boehringer Ingelheim´s investigational treatment of acute myeloid leukaemia, is granted ‘orphan drug designation’ in the EU and the US
17 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the US Food and Drug Administration and the European Commission have granted volasertib* ‘orphan drug designation' for the treatment of patients with acute myeloid leukaemia...
Final data from the Phase 2 COSMOS study of Janssen’s once-daily simeprevir in combination with sofosbuvir presented at The International Liver Congress™ 2014
16 April 2014 | By Janssen
Additional analyses presented in European and hepatitis C genotype 4 patient subgroups underscore benefit of simeprevir-based treatment regimens...
GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™
16 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the US Food and Drug Administration has approved TanzeumTM (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes...
Johnson & Johnson reports 2014 first-quarter results
15 April 2014 | By Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting…
Abbvie announces initiation of pivotal Phase III study of veliparib (abt-888) for patients with non-small cell lung cancer
15 April 2014 | By AbbVie
AbbVie announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib...
Boehringer Ingelheim pleased with 2013 financial year
15 April 2014 | By Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim is pleased with the 2013 financial year...
